It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Check out what’s new with our refreshed design. If you use one of our e-Edition specific apps, you can continue using the same app but will notice some changes. Popular features such as double ...

One thing Merck does not have is its own version of the hot new weight-loss medicines that have made Eli Lilly and Novo ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Fortune Recommends™ Health is editorially independent. We may earn affiliate revenue from links in this content. Learn more . Fortune Recommends™ is editorially independent. We earn a commission for ...

3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field In a second setback for Keytruda that Merck unveiled Thursday, the New Jersey pharma is discontinuing the phase 3 ...

The new agreement comes shortly after Merck started working with B Braun subsidiary neuroloop on vagus nerve-stimulating therapies for inflammatory diseases. Bioelectronic medicine focuses on the ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck (NYSE: MRK) is a top pharmaceutical company ... One of the keys to replacing the lost revenue will be new drugs, including Winrevair, a treatment for pulmonary arterial hypertension.

The Merck Manuals Online Medical Library Clinical Pharmacology Section: provides a general review of pharmacokinetic parameters: absorption, bioavailability, distribution, excretion and metabolism ...